Abstract

Cognitively impaired and spared patient subgroups were identified in psychosis and depression, and in clinical high-risk for psychosis (CHR). Studies suggest differences in underlying brain structural and functional characteristics. It is unclear whether cognitive subgroups are transdiagnostic phenomena in early stages of psychotic and affective disorder which can be validated on the neural level. Patients with recent-onset psychosis (ROP; N = 140; female = 54), recent-onset depression (ROD; N = 130; female = 73), CHR (N = 128; female = 61) and healthy controls (HC; N = 270; female = 165) were recruited through the multi-site study PRONIA. The transdiagnostic sample and individual study groups were clustered into subgroups based on their performance in eight cognitive domains and characterized by gray matter volume (sMRI) and resting-state functional connectivity (rsFC) using support vector machine (SVM) classification. We identified an impaired subgroup (N ROP  = 79, N ROD  = 30, N CHR  = 37) showing cognitive impairment in executive functioning, working memory, processing speed and verbal learning (all p < 0.001). A spared subgroup (N ROP  = 61, N ROD  = 100, N CHR  = 91) performed comparable to HC. Single-disease subgroups indicated that cognitive impairment is stronger pronounced in impaired ROP compared to impaired ROD and CHR. Subgroups in ROP and ROD showed specific symptom- and functioning-patterns. rsFC showed superior accuracy compared to sMRI in differentiating transdiagnostic subgroups from HC (BAC impaired  = 58.5%; BAC spared  = 61.7%, both: p < 0.01). Cognitive findings were validated in the PRONIA replication sample (N = 409). Individual cognitive subgroups in ROP, ROD and CHR are more informative than transdiagnostic subgroups as they map onto individual cognitive impairment and specific functioning- and symptom-patterns which show limited overlap in sMRI and rsFC. CLINICAL TRIAL REGISTRY NAME: German Clinical Trials Register (DRKS). Clinical trial registry URL: https://www.drks.de/drks_web/ . Clinical trial registry number: DRKS00005042.

Original languageEnglish
JournalNeuropsychopharmacology
Volume49
Issue number3
Pages (from-to)573-583
Number of pages11
ISSN0893-133X
DOIs
Publication statusPublished - 02.2024

Funding

FundersFunder number
Koeln Fortune Program/Faculty of Medicine, University of Cologne370/2020
NHMRC-EU1075379
National Institute of Mental HealthT32MH122394
Brain and Behavior Research Foundation28474
National Alliance for Research on Schizophrenia and Depression
Medical Research Council
National Institute for Health and Care Research
National Health and Medical Research Council1105825, 1196508
Rebecca L. Cooper Medical Research Foundation

    Research Areas and Centers

    • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

    DFG Research Classification Scheme

    • 2.23-10 Clinical Psychiatry, Psychotherapy, Child and Adolescent Psychiatry
    • 2.23-08 Human Cognitive and Systems Neuroscience

    Fingerprint

    Dive into the research topics of 'Transdiagnostic subgroups of cognitive impairment in early affective and psychotic illness'. Together they form a unique fingerprint.

    Cite this